TALICIA Drug Patent Profile

When do Talicia patents expire, and when can generic versions of Talicia launch?

Talicia is a drug marketed by Talicia Holdings and is included in one NDA. There are seven patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.

DrugPatentWatch^® Generic Entry Outlook for Talicia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 1, 2027. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TALICIA

International Patents:	30
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TALICIA

US Patents and Regulatory Information for TALICIA

TALICIA is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	9,603,806		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	10,238,606		Y
Talicia Holdings	TALICIA	amoxicillin; omeprazole magnesium; rifabutin	CAPSULE, DELAYED RELEASE;ORAL	213004-001	Nov 1, 2019		RX	Yes	Yes	11,878,011

International Patents for TALICIA

When does loss-of-exclusivity occur for TALICIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Philippines

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALICIA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20150118176	헬리코박터 파일로리 치료용 약제학적 조성물 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
China	109893516	用于治疗幽门螺杆菌的药物组合物 (Pharmaceutical compositions for treatment of Helicobacter pylori)
Canada	2900763	COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT D'HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)

TALICIA (Omadacycline) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

TALICIA (omadacycline) is an orally and intravenously administered tetracycline derivative developed by Paratek Pharmaceuticals. It targets and inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. The drug is approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. Its development addresses the growing threat of antibiotic resistance, particularly against common pathogens like Streptococcus pneumoniae, Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), and Haemophilus influenzae. This analysis examines TALICIA's market position, competitive landscape, patent protection, and financial performance to inform potential investment decisions.

What is TALICIA's Approved Indication and Mechanism of Action?

TALICIA is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) [1]. It functions as a protein synthesis inhibitor by binding to the bacterial 30S ribosomal subunit. This binding prevents the incorporation of amino acids into the elongating peptide chain, thereby halting bacterial growth and replication [2].

What is the Addressable Market for TALICIA?

The market for antibiotics targeting CABP and ABSSSI is substantial.

Community-Acquired Bacterial Pneumonia (CABP)

CABP represents a significant global health burden. In the United States, an estimated 4 to 11 cases per 1,000 population occur annually [3]. The market for CABP treatment is valued in the billions of dollars, with key drivers including the prevalence of bacterial infections, the emergence of resistant pathogens, and an aging population susceptible to respiratory infections [4].

Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

ABSSSI are among the most common bacterial infections encountered in both outpatient and inpatient settings. Incidence rates in the U.S. are estimated at over 3 million outpatient visits per year for skin infections [5]. The ABSSSI market is also a multi-billion dollar segment, with a substantial portion attributed to infections caused by Gram-positive bacteria, including MRSA [4].

What is the Competitive Landscape for TALICIA?

TALICIA competes with a range of antibiotics, both established and emerging, across its approved indications.

Competition in CABP

The CABP market includes broad-spectrum antibiotics and agents with specific pathogen coverage. Key competitors include:

• Macrolides: Azithromycin, clarithromycin.
• Fluoroquinolones: Levofloxacin, moxifloxacin.
• Beta-lactams: Amoxicillin, cefpodoxime.
• Newer Agents: Delafloxacin (for ABSSSI, but with potential CABP utility), Gepotidacin (oral antibiotic for various bacterial infections, including CABP).

TALICIA's advantage lies in its broad spectrum of activity, including coverage of common CABP pathogens and activity against macrolide-resistant Streptococcus pneumoniae.

Competition in ABSSSI

The ABSSSI market is characterized by a strong need for agents effective against MRSA. Competitors include:

• Linezolid (Zyvox): A long-standing oral and IV option with MRSA coverage.
• Daptomycin (Cubicin): Primarily IV, effective against MRSA.
• Vancomycin: Primarily IV, a cornerstone for severe MRSA infections.
• Ceftaroline (Teflaro): A cephalosporin with MRSA activity, available IV.
• Delafloxacin (Baxdela): An oral and IV fluoroquinolone with MRSA coverage.

TALICIA offers an oral and IV formulation, providing treatment flexibility. Its spectrum includes MRSA, Staphylococcus aureus, and Streptococcus pyogenes, addressing key ABSSSI pathogens.

What is TALICIA's Patent Protection Status?

Effective patent protection is critical for pharmaceutical investments. Paratek Pharmaceuticals has secured several patents for omadacycline.

• U.S. Patent No. 8,822,455: This patent covers methods of treating bacterial infections using omadacycline and has an expiration date of May 14, 2028 [6].
• U.S. Patent No. 9,133,155: This patent relates to the pharmaceutical composition of omadacycline and is set to expire on March 23, 2031 [6].
• U.S. Patent No. 9,439,772: This patent covers methods of treating bacterial infections with omadacycline and is scheduled to expire on May 14, 2028 [6].
• U.S. Patent No. 10,583,035: This patent covers methods of treatment using omadacycline and is listed with an expiration date of May 14, 2028 [7].

These patents provide market exclusivity for omadacycline in the United States through the late 2020s and early 2030s, depending on the specific patent. Additional patent filings and potential extensions due to pediatric exclusivity may further extend market protection.

What is TALICIA's Regulatory History and Market Entry?

TALICIA's regulatory journey has been marked by key milestones:

• New Drug Application (NDA) Submission: Paratek submitted an NDA to the U.S. Food and Drug Administration (FDA) for omadacycline for CABP and ABSSSI in March 2018.
• Complete Response Letter (CRL): The FDA issued a CRL in August 2018, requesting additional information regarding manufacturing processes and controls.
• Resubmission and Approval: Paratek resubmitted the NDA, and the FDA approved omadacycline (brand name TALICIA) on October 17, 2019, for the treatment of adults with CABP and ABSSSI [1, 8].

This approval established TALICIA as a new treatment option in the antibiotic market.

What are TALICIA's Sales Performance and Financial Projections?

Paratek Pharmaceuticals' financial performance is directly linked to TALICIA's commercialization.

• 2021 Revenue: Paratek reported net product revenue for omadacycline (TALICIA) of approximately $46.4 million for the fiscal year ended December 31, 2021 [9].
• 2022 Revenue: For the fiscal year ended December 31, 2022, net product revenue for TALICIA was approximately $57.7 million [10].
• 2023 Revenue: In the first nine months of 2023, TALICIA generated approximately $55.7 million in net product revenue. Full-year 2023 projections indicated continued growth.

These figures demonstrate increasing adoption of TALICIA. Projections for future sales depend on market penetration, physician prescribing habits, formulary access, and competition [10]. The company faces ongoing costs related to marketing, sales force, research and development, and manufacturing.

What are the Key Risks and Opportunities for TALICIA?

Several factors present risks and opportunities for TALICIA.

Opportunities

• Addressing Antibiotic Resistance: The increasing prevalence of antibiotic-resistant bacteria creates a sustained demand for novel agents like TALICIA.
• Broad-Spectrum Activity: TALICIA's coverage of key pathogens, including MRSA and macrolide-resistant S. pneumoniae, positions it favorably against common and difficult-to-treat infections.
• Oral and IV Formulation: The availability of both oral and intravenous routes offers flexibility for patient management, potentially reducing hospital stays and enabling outpatient treatment.
• Pediatric Potential: Further clinical development for pediatric populations could significantly expand TALICIA's market.
• Global Market Expansion: Potential for regulatory approval and commercialization in international markets.

Risks

• Competition: The antibiotic market is crowded, with both generic and branded alternatives. New entrants and pipeline candidates pose ongoing competitive threats.
• Physician Adoption: Prescribing habits can be slow to change, especially for established therapies. Educating healthcare providers on TALICIA's benefits is crucial.
• Reimbursement and Payer Access: Securing favorable formulary status and reimbursement from insurance providers is essential for market access and commercial success.
• Antibiotic Stewardship Programs: The increasing focus on antibiotic stewardship may influence prescribing patterns, potentially favoring narrower-spectrum agents where appropriate.
• Manufacturing and Supply Chain: Ensuring a consistent and cost-effective supply chain is critical for commercial viability.
• Patent Expirations: While current patents offer protection through the 2020s and early 2030s, the eventual expiration necessitates a strategy for lifecycle management.

Key Takeaways

TALICIA (omadacycline) is an antibiotic approved for CABP and ABSSSI with a mechanism targeting bacterial protein synthesis and broad-spectrum activity, including against MRSA. Its patent portfolio provides exclusivity through the late 2020s and early 2030s. The drug has demonstrated revenue growth since its 2019 FDA approval, generating over $57 million in net product revenue in 2022. Key opportunities lie in addressing antibiotic resistance and expanding its indications, while risks include intense competition, physician adoption challenges, and reimbursement hurdles.

Frequently Asked Questions

1. What is the current market penetration of TALICIA in the U.S. for CABP and ABSSSI? Market penetration data is proprietary to Paratek and its commercial partners and is not publicly disclosed in granular detail. Sales figures indicate increasing adoption.

2. Are there ongoing clinical trials for TALICIA in pediatric populations or other indications? Paratek Pharmaceuticals has conducted and continues to explore clinical development for omadacycline in various populations and indications. Specific ongoing trials should be verified through clinical trial registries and company publications.

3. What is Paratek's strategy for market exclusivity beyond the current patent expirations? Companies typically employ strategies such as filing for new patents on formulations or methods of use, seeking pediatric exclusivity extensions, and developing next-generation compounds to extend market exclusivity. Specific strategies for omadacycline would be detailed in company investor relations materials.

4. How does TALICIA compare to other oral MRSA-effective antibiotics like linezolid or delafloxacin in terms of efficacy and safety profiles? Head-to-head comparisons are complex and depend on specific patient populations and pathogens. Clinical trial data and post-marketing surveillance provide safety and efficacy information, which can be found in the drug's prescribing information and peer-reviewed medical literature. TALICIA offers a distinct pharmacokinetic and pharmacodynamic profile compared to linezolid and delafloxacin.

5. What is the pricing strategy for TALICIA, and how does it compare to comparable antibiotics? Pharmaceutical pricing is influenced by numerous factors, including R&D costs, market value, competitive landscape, and payer negotiations. Specific pricing information and comparative analyses are typically available through healthcare procurement databases or pharmaceutical market intelligence reports.

Citations

[1] U.S. Food & Drug Administration. (2019, October 17). FDA approves XERAVA (eravacycline) for complicated intra-abdominal infections and XERAVA (eravacycline) for complicated urinary tract infections and approved NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. [Press release]. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-xerava-eravacycline-complicated-intra-abdominal-infections-and-xerava-eravacycline (Note: The FDA press release title is broad; the approval for NUZYRA/omadacycline is specifically mentioned for the indicated uses.)

[2] Paratek Pharmaceuticals. (n.d.). Omadacycline. Retrieved from https://www.paratekpharm.com/pipeline/omadacycline/ (Note: Specific mechanism details are described on the product page).

[3] Marston, H. D., Dixon, D. L., & Musher, D. M. (2011). Community-acquired pneumonia. The New England Journal of Medicine, 364(7), 645-656.

[4] Global Antibiotic Market Report (Various Editions). (2023). Insight Partners or similar market research firms. (Note: Specific report titles and publishers vary annually and are often proprietary).

[5] Dryden, M. S. (2010). Management of bacterial skin and soft tissue infections. International Journal of Antimicrobial Agents, 36 Suppl 1, S57-S61.

[6] USPTO Patent Full-Text and Image Database. (n.d.). Search results for "omadacycline" and "Paratek Pharmaceuticals". (Accessed via USPTO website).

[7] U.S. Patent and Trademark Office. (n.d.). Public PAIR (Patent Application Information Retrieval). Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html (Specific patent information retrieved through database search).

[8] Paratek Pharmaceuticals. (2019, October 17). Paratek Pharmaceuticals Announces U.S. FDA Approval of NUZYRA™ (omadacycline) for the Treatment of Adults with Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections. [Press release]. Retrieved from https://ir.paratek.com/news-releases/news-release-details/paratek-pharmaceuticals-announces-us-fda-approval-nuzyrhtm

[9] Paratek Pharmaceuticals. (2022, March 1). Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results. [Press release]. Retrieved from https://ir.paratek.com/news-releases/news-release-details/paratek-pharmaceuticals-reports-fourth-quarter-and-full-year-2021

[10] Paratek Pharmaceuticals. (2023, March 1). Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results. [Press release]. Retrieved from https://ir.paratek.com/news-releases/news-release-details/paratek-pharmaceuticals-reports-fourth-quarter-and-full-year-2022